These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 31219362)

  • 1. Improvement in liver steatosis after the switch from a ritonavir-boosted protease inhibitor to raltegravir in HIV-infected patients with non-alcoholic fatty liver disease.
    Calza L; Colangeli V; Borderi M; Coladonato S; Tazza B; Fornaro G; Badia L; Guardigni V; Verucchi G; Viale P
    Infect Dis (Lond); 2019 Aug; 51(8):593-601. PubMed ID: 31219362
    [No Abstract]   [Full Text] [Related]  

  • 2. Changes in Liver Steatosis After Switching From Efavirenz to Raltegravir Among Human Immunodeficiency Virus-Infected Patients With Nonalcoholic Fatty Liver Disease.
    Macías J; Mancebo M; Merino D; Téllez F; Montes-Ramírez ML; Pulido F; Rivero-Juárez A; Raffo M; Pérez-Pérez M; Merchante N; Cotarelo M; Pineda JA;
    Clin Infect Dis; 2017 Sep; 65(6):1012-1019. PubMed ID: 28903510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Substitution of nevirapine or raltegravir for protease inhibitor vs. rosuvastatin treatment for the management of dyslipidaemia in HIV-infected patients on stable antiretroviral therapy (Nevrast study).
    Calza L; Magistrelli E; Colangeli V; Borderi M; Bussini L; Bon I; Re MC; Viale P
    Infect Dis (Lond); 2017 Oct; 49(10):737-747. PubMed ID: 28683645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improvement in insulin sensitivity and serum leptin concentration after the switch from a ritonavir-boosted PI to raltegravir or dolutegravir in non-diabetic HIV-infected patients.
    Calza L; Colangeli V; Borderi M; Coladonato S; Tazza B; Bon I; Re MC; Viale P
    J Antimicrob Chemother; 2019 Mar; 74(3):731-738. PubMed ID: 30541118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study.
    Boyd MA; Amin J; Mallon PW; Kumarasamy N; Lombaard J; Wood R; Chetchotisakd P; Phanuphak P; Mohapi L; Azwa I; Belloso WH; Molina JM; Hoy J; Moore CL; Emery S; Cooper DA;
    Lancet HIV; 2017 Jan; 4(1):e13-e20. PubMed ID: 27815068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study.
    Martínez E; Larrousse M; Llibre JM; Gutiérrez F; Saumoy M; Antela A; Knobel H; Murillas J; Berenguer J; Pich J; Pérez I; Gatell JM;
    AIDS; 2010 Jul; 24(11):1697-707. PubMed ID: 20467288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual Raltegravir-Darunavir/Ritonavir Combination in Virologically Suppressed HIV-1-Infected Patients on Antiretroviral Therapy Including a Ritonavir-Boosted Protease Inhibitor Plus Two Nucleoside/Nucleotide Reverse Transcriptase Inhibitors.
    Calza L; Danese I; Magistrelli E; Colangeli V; Manfredi R; Bon I; Re MC; Conti M; Viale P
    HIV Clin Trials; 2016 Feb; 17(1):38-47. PubMed ID: 26728706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switch to a raltegravir-based antiretroviral regimen in people with HIV and non-alcoholic fatty liver disease: A randomized controlled trial.
    Shengir M; Lebouche B; Elgretli W; Saeed S; Ramanakumar AV; Giannakis A; De Pokomandy A; Cox J; Costiniuk C; Routy JP; Klein MB; Sebastiani G
    HIV Med; 2024 Jan; 25(1):135-142. PubMed ID: 37641534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adiponectin and the steatosis marker Chi3L1 decrease following switch to raltegravir compared to continued PI/NNRTI-based antiretroviral therapy.
    Offor O; Utay N; Reynoso D; Somasunderam A; Currier J; Lake J
    PLoS One; 2018; 13(5):e0196395. PubMed ID: 29746485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma concentrations of efavirenz, darunavir/ritonavir and raltegravir in HIV-HCV-coinfected patients without liver cirrhosis in comparison with HIV-monoinfected patients.
    Calza L; Danese I; Colangeli V; Manfredi R; Magistrelli E; Verucchi G; Conti M; Motta R; Viale P
    Infect Dis (Lond); 2015 Sep; 47(9):625-36. PubMed ID: 25875396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of prior virological failure and nucleos(t)ide genotypic resistance mutations on the efficacy of switching from ritonavir-boosted protease inhibitors to raltegravir.
    Blanco JL; Gonzalez-Cordón A; Llibre JM; Calvo M; Gutierrez F; Podzamczer D; Laguno M; Fumero E; Murillas J; Mallolas J; Martinez-Rebollar M; Lonca M; Perez I; Gatell JM; Martinez E
    Antivir Ther; 2015; 20(5):487-92. PubMed ID: 24964358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of intensification with raltegravir on HIV-1-infected individuals receiving monotherapy with boosted PIs.
    Puertas MC; Gómez-Mora E; Santos JR; Moltó J; Urrea V; Morón-López S; Hernández-Rodríguez A; Marfil S; Martínez-Bonet M; Matas L; Muñoz-Fernández MA; Clotet B; Blanco J; Martinez-Picado J
    J Antimicrob Chemother; 2018 Jul; 73(7):1940-1948. PubMed ID: 29635527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patients.
    Neukam K; Mira JA; Ruiz-Morales J; Rivero A; Collado A; Torres-Cornejo A; Merino D; de Los Santos-Gil I; Macías J; González-Serrano M; Camacho A; Parra-García G; Pineda JA;
    J Antimicrob Chemother; 2011 Nov; 66(11):2605-14. PubMed ID: 21903660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in liver steatosis evaluated by transient elastography with the controlled attenuation parameter in HIV-infected patients.
    Macías J; Real LM; Rivero-Juárez A; Merchante N; Camacho A; Neukam K; Rivero A; Mancebo M; Pineda JA
    HIV Med; 2016 Nov; 17(10):766-773. PubMed ID: 27028546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvement in renal function and bone mineral density after a switch from tenofovir/emtricitabine plus ritonavir-boosted protease inhibitor to raltegravir plus nevirapine: a pilot study.
    Calza L; Magistrelli E; Colangeli V; Borderi M; Conti M; Mancini R; Viale P
    Antivir Ther; 2016; 21(3):217-24. PubMed ID: 26405177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.
    Reynes J; Lawal A; Pulido F; Soto-Malave R; Gathe J; Tian M; Fredrick LM; Podsadecki TJ; Nilius AM
    HIV Clin Trials; 2011; 12(5):255-67. PubMed ID: 22180523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A reduced grade of liver fibro-steatosis after raltegravir, maraviroc and fosamprenavir in an HIV/HCV co-infected patient with chronic hepatitis, cardiomyopathy, intolerance to nelfinavir and a marked increase of serum creatine phosphokinase levels probably related to integrase inhibitor use.
    Degli Antoni A; Weimer LE; Manfredi R; Fragola V; Ferrari C
    West Indian Med J; 2012 Dec; 61(9):932-6. PubMed ID: 24020238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maraviroc, as a Switch Option, in HIV-1-infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH Study.
    Pett SL; Amin J; Horban A; Andrade-Villanueva J; Losso M; Porteiro N; Sierra Madero J; Belloso W; Tu E; Silk D; Kelleher A; Harrigan R; Clark A; Sugiura W; Wolff M; Gill J; Gatell J; Fisher M; Clarke A; Ruxrungtham K; Prazuck T; Kaiser R; Woolley I; Arnaiz JA; Cooper D; Rockstroh JK; Mallon P; Emery S;
    Clin Infect Dis; 2016 Jul; 63(1):122-32. PubMed ID: 27048747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study.
    McComsey G; Bhumbra N; Ma JF; Rathore M; Alvarez A;
    Pediatrics; 2003 Mar; 111(3):e275-81. PubMed ID: 12612284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257.
    Ofotokun I; Na LH; Landovitz RJ; Ribaudo HJ; McComsey GA; Godfrey C; Aweeka F; Cohn SE; Sagar M; Kuritzkes DR; Brown TT; Patterson KB; Para MF; Leavitt RY; Villasis-Keever A; Baugh BP; Lennox JL; Currier JS;
    Clin Infect Dis; 2015 Jun; 60(12):1842-51. PubMed ID: 25767256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.